FDA meeting streamlines pathway to initial U.S. approval of Provectus's PV-10 oncolog

[News]

Provectus Biopharmaceuticals, Inc. (PVCT), a development-stage oncology and dermatology biopharmaceutical company, today announced that it has received the official minutes from the Type C meeting held with the FDA's Division of Oncology Products 2 on December 16, 2013.

More... (http://www.news-medical.net/news/20140127/FDA-meeting-streamlines-pathway-to-initial-US-approval-of-Provectuss-PV-10-oncology-drug.aspx)